{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 123,
  "pageCount": 239,
  "prevPage": 122,
  "nextPage": 124,
  "slideType": "quote_slide",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide uses expert testimony to frame Nevro's business model as unsustainable once 'low-hanging fruit' markets are exhausted.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/123",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-123",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "We can see from spreadsheets where our sales have accelerated or decelerated relative to Nevro’s presence. We know from data that if you do a clinical trial in a hospital, your sales there accelerate. We definitely saw growth decelerating for Nevro.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b340-796c8238ae24",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "quote",
      "text": "An executive in Medtronic’s spinal cord stimulation division explained Nevro’s trajectory in great detail... Nevro’s SCS market share has remained flat at ~15% since 2017.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b28b145-63d7-4475-8e90-30118b8144d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.31
      },
      "kind": "quote",
      "text": "“Nevro cherry-picked the lowest hanging fruit at launch... It’s a lot easier to get from 0% to 15% share than from 15% to 30%.”",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59e5a994-4ce1-45bd-b967-f4c357000aed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.59
      },
      "kind": "quote",
      "text": "“A big piece of their wins were all class 1 teaching hospitals... You need a very different playbook to expand from 15% to 20% share than what Nevro has used.”",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "741d1b7a-ef24-49bc-9a20-ce5c5b778404",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "quote",
      "text": "“When we look at our revenue and where we got beaten... They’ve taken as much share as they’re going to take in class A cities.”",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aacb7165-0490-4157-9ee4-62ea968f67f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.76
      },
      "kind": "quote",
      "text": "“We can see from spreadsheets where our sales have accelerated or decelerated relative to Nevro’s presence... We definitely saw growth decelerating for Nevro.” – Medtronic SCS executive",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb0af23c-7d2a-45ed-8a0e-41319b24a311",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“Nevro cherry-picked the lowest hanging fruit at launch. They went to the 25 best places like New York, Los Angeles, Atlanta. They went to teaching institutions who are receptive to new stuff. It’s a lot easier to get from 0% to 15% share than from 15% to 30%. Zero to 3% is hard, 3% to 10% is easy, and after 15% it’s trying to grow in Buffalo versus New York City.” — Medtronic SCS executive",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b340-7eaae37979d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32bd9893-3d6b-4700-8363-f116188f30ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.05,
        "y": 0.09
      },
      "kind": "title",
      "text": "9. Nevro’s current predicament – a one-tick pony stuck in a ditch – and drivers of its ongoing growth collapse",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "960ec1a2-04bd-4a13-a40a-c43a6b75a47d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e136a0ef-0af3-4db9-9903-e6e5c0685f23",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "antagonist-introduction",
      "slug": null,
      "matchId": "566b77ad-2139-45f1-a674-8ac8f6d9aee8",
      "evidence": "Framing Medtronic as the expert observer exposing Nevro's flaws.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 150,
      "from": 51,
      "beatId": "903c076a-f368-4ca1-844c-277874c1afb2",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The deck presents a conclusion that Nevro's problems are insurmountable",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}